Vivos Therapeutics (NASDAQ:VVOS) reported a 70% year-over-year revenue increase for Q1 2026.
Revenue reached approximately $5.1 million, up from $3.0 million in the same period last year.
The growth was driven by $2.0 million in sleep testing services and $0.9 million from The Sleep Center of Nevada locations acquired in June 2025.
Gross profit rose by $1.5 million to $3.1 million. Gross margin improved to 60% from 50%.
The company sold 5,304 oral appliances, a 42% increase from 3,735 in Q1 2025.
Operating expenses increased 78% to $9.7 million, partly due to non-recurring professional fees of $0.9 million.
Net loss widened to $7.8 million from $3.9 million. Cash and equivalents stood at $2.1 million, with negative equity of $1.1 million.
Cash position is weak: current ratio is 0.24 and levered free cash flow is negative $17.6 million over the last twelve months.
The stock trades at $0.59, near its 52-week low of $0.58.
No new Vivos Integrated Provider dentists enrolled in the quarter, reflecting a shift toward sleep center acquisitions.
Vivos develops medical devices for obstructive sleep apnea.
